TargetBeta
TSLP
thymic stromal lymphopoietin
10 programs in company-led studies act on TSLP, from 10 companies: 5 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| tezepelumabrule | AstraZeneca | phase 4 | 349 running | – | ChEMBL |
| tilrekimig | Pfizer | phase 3 | 119 running | IL13, IL4 | the company's pipeline |
| felcorekibart | GlaxoSmithKline | phase 3 | 99 running | – | the company's pipeline |
| lunsekimig | Sanofi | phase 3 | 106 running | IL13 | the company's pipeline |
| SHR-1905 | Jiangsu HengRui Medicine | phase 3 | 73 running | – | the company's pipeline |
| TQC2731 | Sino Biopharmaceutical | phase 3 | 73 running | – | the company's pipeline |
| WIN378rule | Windward Bio | phase 2 | 22 running | – | the studies' text |
| CDX-622rule | Celldex Therapeutics | phase 1 | 21 running | KITLG | the studies' text |
| HXN-1013rule | Helixon Biotechnology (Suzhou) | phase 1 | 11 running | IL33 | the studies' text |
| HY6725rule | Newsoara Biopharma | phase 1 | 11 running | IL33 | the studies' text |
Conditions their studies are in
- Asthma, 9 programs
- Pulmonary Disease, Chronic Obstructive, 6 programs
- Nasal Polyps, 5 programs
- Dermatitis, Atopic, 4 programs
- Rhinosinusitis, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026TQC2731 · Sino Biopharmaceutical · phase 3 · NCT06707883
- Jan 13, 2027tezepelumab · AstraZeneca · phase 4 · NCT06706817
- Feb 20, 2027tilrekimig · Pfizer · phase 3 · NCT07792941
- Mar 2027CDX-622 · Celldex Therapeutics · phase 1 · NCT07330778
- Mar 2027HY6725 · Newsoara Biopharma · phase 1 · NCT07262281
- Apr 13, 2027felcorekibart · GlaxoSmithKline · phase 3 · NCT07712393
- Jun 21, 2027lunsekimig · Sanofi · phase 3 · NCT06676319
- Dec 17, 2027WIN378 · Windward Bio · phase 2 · NCT07646587
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.